Xiaoyan Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyan Lv has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aliza Paudyal
Department of Dermatology and Venerology B. P. Koirala Institute of Health Sciences Dharan Nepal
2 shared publications Christina Thapa
Department of Dermatology and Venerology, West China Hospital Sichuan University Chengdu China
2 shared publicationsShirui Gong
Department of Dermatology and Venerology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
2 shared publications- Hang Zhou1 shared publication
- Jianing Liu
Division of Molecular Nephrology and The Creative Training Center for Undergraduates, The Ministry of Education Key Laboratory of Clinical Diagnostics, School of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China
1 shared publication Jin Hao
Department of Dermatology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, PR China; The Division of Molecular Nephrology And the Creative Training Center for Undergraduates, the M.O.E. Key Laboratory of Laboratory Medical Diagnostics, the College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China
1 shared publication
Latest Publications
- 9 October 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (3) , e62-e63
Livedo reticularis and flagellate erythema in adult dermatomyositis: a rare cutaneous presentation
- 9 October 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (3) , e62-e63
Livedo reticularis and flagellate erythema in adult dermatomyositis: a rare cutaneous presentation
- 13 March 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3) , e14939
JAK‐inhibitors for dermatomyositis: A concise literature review
Refractory dermatomyositis (DM) is defined as cases that do not show improvement after initial treatment with two different immunosuppressives combined with corticosteroids with or without intravenous immunoglobulins. In recent years, few studies have reported a positive response to the use of Janus kinase inhibitors (JAK‐inhibitors) for the treatment of refractory DM. A systematic literature review was performed for articles studying the use of JAK‐inhibitors for the treatment of refractory DM. We identified 38 females and 15 males treated with JAK‐inhibitors without serious side effects. Tofacitinib was the most frequently used JAK‐inhibitor followed by ruxolitinib. Significant improvement in CDASI score, muscle strength, body weight, and skin lesions were reported in most of the studies. The duration of follow‐up ranged from 1 to 15 months without relapse. Therefore, the use of JAK‐inhibitors looks promising in the treatment of refractory DM and further high volume research may be required to validate the current concept. As only case reports and series were identified without direct comparison for review, there is a potential risk of bias. Despite these limitations, we believe that the result of this analysis allows a better understanding of treatment options for refractory DM and will help generate a hypothesis that can be further tested.
- 13 March 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3) , e14939
JAK‐inhibitors for dermatomyositis: A concise literature review
Refractory dermatomyositis (DM) is defined as cases that do not show improvement after initial treatment with two different immunosuppressives combined with corticosteroids with or without intravenous immunoglobulins. In recent years, few studies have reported a positive response to the use of Janus kinase inhibitors (JAK‐inhibitors) for the treatment of refractory DM. A systematic literature review was performed for articles studying the use of JAK‐inhibitors for the treatment of refractory DM. We identified 38 females and 15 males treated with JAK‐inhibitors without serious side effects. Tofacitinib was the most frequently used JAK‐inhibitor followed by ruxolitinib. Significant improvement in CDASI score, muscle strength, body weight, and skin lesions were reported in most of the studies. The duration of follow‐up ranged from 1 to 15 months without relapse. Therefore, the use of JAK‐inhibitors looks promising in the treatment of refractory DM and further high volume research may be required to validate the current concept. As only case reports and series were identified without direct comparison for review, there is a potential risk of bias. Despite these limitations, we believe that the result of this analysis allows a better understanding of treatment options for refractory DM and will help generate a hypothesis that can be further tested.
- 2 December 2019
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 31 (1) , 61-65
A retrospective analysis of infections and antibiotic treatment in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare drug-related life-threatening acute conditions. Infection is a major cause of morbidity and mortality in these patients. The aim of this study was to analyze the infective characteristics and antimicrobial strategies in patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Methods: 125 patients who were diagnosed with SJS/TEN in West China Hospital from 2010 to 2017 were retrospectively analyzed. Results: There were 75 patients with coinfections (75/125, 60%), of whom 44 had SJS (44/90, 48.9%) and 31 had TEN (31/35, 88.6%). The most common infections were skin infections and pulmonary infections. Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) were the most frequently identified pathogenic organisms. The most common antibiotics used in patients with infections were vancomycin, carbapenems, quinolones, macrolides and lincomycin. Conclusions: Antimicrobial therapy should be administered promptly if there are clinical signs of an infection. Empiric antibiotic selection is based on knowledge of the local microbiota, the different infected sites, the pathogens involved and the severity of disease.
- 2 December 2019
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 31 (1) , 61-65
A retrospective analysis of infections and antibiotic treatment in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare drug-related life-threatening acute conditions. Infection is a major cause of morbidity and mortality in these patients. The aim of this study was to analyze the infective characteristics and antimicrobial strategies in patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Methods: 125 patients who were diagnosed with SJS/TEN in West China Hospital from 2010 to 2017 were retrospectively analyzed. Results: There were 75 patients with coinfections (75/125, 60%), of whom 44 had SJS (44/90, 48.9%) and 31 had TEN (31/35, 88.6%). The most common infections were skin infections and pulmonary infections. Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) were the most frequently identified pathogenic organisms. The most common antibiotics used in patients with infections were vancomycin, carbapenems, quinolones, macrolides and lincomycin. Conclusions: Antimicrobial therapy should be administered promptly if there are clinical signs of an infection. Empiric antibiotic selection is based on knowledge of the local microbiota, the different infected sites, the pathogens involved and the severity of disease.
- 1 July 2018
- Published by Elsevier in Experimental Cell Research
- Vol. 368 (2) , 167-173
ER-localized protein-Herpud1 is a new mediator of IL-4-induced macrophage polarization and migration
- 1 July 2018
- Published by Elsevier in Experimental Cell Research
- Vol. 368 (2) , 167-173
ER-localized protein-Herpud1 is a new mediator of IL-4-induced macrophage polarization and migration
- 1 August 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 357 (2) , 155-162
Involvement of JNK signaling in IL4-induced M2 macrophage polarization
- 1 August 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 357 (2) , 155-162
Involvement of JNK signaling in IL4-induced M2 macrophage polarization